Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LPTX 
Leap Therapeutics Inc (LPTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: LPTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.2% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.11M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta -0.06 | 52 Weeks Range 0.22 - 4.79 | Updated Date 10/25/2025 |
52 Weeks Range 0.22 - 4.79 | Updated Date 10/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -77.23% | Return on Equity (TTM) -183.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12159856 | Price to Sales(TTM) 160.1 |
Enterprise Value 12159856 | Price to Sales(TTM) 160.1 | ||
Enterprise Value to Revenue 1.9 | Enterprise Value to EBITDA 0.47 | Shares Outstanding 56651840 | Shares Floating 30425317 |
Shares Outstanding 56651840 | Shares Floating 30425317 | ||
Percent Insiders 11.85 | Percent Institutions 30.6 |
Upturn AI SWOT
Leap Therapeutics Inc
Company Overview
History and Background
Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted immuno-oncology therapeutics. Founded in 2011, it aims to develop novel therapies that can potentially provide better outcomes for patients with cancer. The company has evolved from early-stage research to clinical-stage drug development.
Core Business Areas
- Drug Development: Focuses on discovering and developing innovative therapies for cancer, primarily in immuno-oncology.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates in various cancer types.
- Partnerships: Collaborates with other pharmaceutical companies and research institutions to advance its drug development programs.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical and biotech industries. The organizational structure includes departments for research and development, clinical operations, regulatory affairs, and commercial strategy.
Top Products and Market Share
Key Offerings
- DKN-01: A humanized IgG1 monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being evaluated in clinical trials for various advanced solid tumors. No significant market share data is available as it is still in development. Competitors include companies developing other immuno-oncology therapies for similar cancer indications such as Merck (Keytruda), Bristol-Myers Squibb (Opdivo), and Roche (Tecentriq).
- FL-301: A novel antibody targeting Claudin18.2. FL-301 is being evaluated in clinical trials for gastric and gastroesophageal junction cancers. No significant market share data is available as it is still in development. Competitors include Astellas (zolbetuximab) and other companies developing similar Claudin18.2-targeting therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory scrutiny, and intense competition. Immuno-oncology is a rapidly growing segment, driven by the increasing understanding of the role of the immune system in cancer.
Positioning
Leap Therapeutics is positioned as a company focused on developing novel immuno-oncology therapies targeting specific proteins involved in cancer growth and progression. Its competitive advantage lies in its proprietary antibody development platform and targeted approach.
Total Addressable Market (TAM)
The global immuno-oncology market is expected to reach hundreds of billions of dollars in the coming years. Leap Therapeutics aims to capture a portion of this market with its innovative therapies, positioning itself in niche areas with high unmet medical needs. Precise TAM figures are dependent on specific indications.
Upturn SWOT Analysis
Strengths
- Proprietary antibody development platform
- Targeted immuno-oncology approach
- Experienced management team
- Strong intellectual property position
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Early-stage pipeline
- No currently marketed products
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Regulatory approval of lead product candidates
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- MRK
- BMY
- AZN
- ASTE
Competitive Landscape
Leap Therapeutics faces intense competition from larger, more established pharmaceutical companies with greater financial resources and broader product portfolios. Leap's advantage lies in its innovative targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its drug candidates through clinical trials and securing financing to support these activities.
Future Projections: Future growth is dependent on the successful completion of clinical trials and potential regulatory approval of its lead product candidates. Analyst estimates vary widely due to the inherent uncertainty in drug development.
Recent Initiatives: Recent initiatives include initiating new clinical trials, presenting clinical data at scientific conferences, and seeking partnerships to expand its development programs.
Summary
Leap Therapeutics is a clinical-stage biopharmaceutical company with promising immuno-oncology assets, but it faces significant financial and competitive challenges. Positive clinical trial outcomes and strategic partnerships are critical for its success. Its DKN-01 and FL-301 product candidates represent key opportunities. Investors need to carefully consider the risks and rewards associated with investing in this early-stage company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Leap Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Leap Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2017-01-25 | CFO, General Counsel, Treasurer & Secretary, President, CEO & Director Mr. Douglas E. Onsi J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://www.leaptx.com |
Full time employees 52 | Website https://www.leaptx.com | ||
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.